<DOC>
	<DOCNO>NCT03071276</DOCNO>
	<brief_summary>This study do two part : Phase I ( NCT02212561 ) complete publish . The goal Phase I portion study find high tolerable dose selinexor ( KPT-330 ) give patient leukemia myelodysplastic syndrome ( MDS ) , combine fludarabine cytarabine . The Phase II portion protocol reflect registration . The goal Phase II portion protocol give high dose selinexor ( KPT-330 ) combination fludarabine/cytarabine find Phase I safe child acute myeloid leukemia ( AML ) . The investigator examine effect combination treatment .</brief_summary>
	<brief_title>Selinexor Combination With Fludarabine Cytarabine Patients With Refractory Relapsed Acute Myeloid Leukemia</brief_title>
	<detailed_description>After recommend Phase II dose determine , additional patient begin enrol receive selinexor recommend dose level evaluation tolerability response . PRIMARY OBJECTIVE : - To estimate overall response rate , define complete response complete response incomplete count recovery , selinexor combination fludarabine cytarabine patient relapse refractory AML phase II portion study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
	<mesh_term>Cortisol succinate</mesh_term>
	<mesh_term>Hydrocortisone acetate</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<criteria>Participants must diagnosis AML must disease relapsed refractory chemotherapy , relapse hematopoietic stem cell transplantation ( HSCT ) Refractory disease define persistent disease least two course induction chemotherapy . Patients eligible first subsequent relapse , whereas patient ALL eligible second subsequent relapse relapse refractory salvage chemotherapy . Patients must ≥ 5 % leukemic blast bone marrow and/or increase level MRD bone marrow assess flow cytometry . If adequate bone marrow sample obtain , patient may enrol unequivocal evidence leukemia peripheral blood . Adequate organ function define follow : Direct bilirubin ≤ 1.5 x institutional upper limit normal ( IULN ) AST ( SGOT ) /ALT ( SGPT ) &lt; 3 x IULN Creatinine within normal institutional limit age Prothrombin time ( PT ) partial thromboplastin ( PTT ) ≤ 1.5 x IULN . Age criterion : Patients treat collaborate site current St. Jude patient therapy within 3 year completion therapy must ≤ 24 year old . All St. Jude patient must &lt; 21 year old . Patients must able swallow tablet . Performance status : Lansky ≥ 50 patient ≤ 16 year old Karnofsky ≥ 50 % patient &gt; 16 year old . Patients must fully recover acute effect prior therapy . For patient receive prior HSCT , evidence GVHD great 60 day must elapse since HSCT . History cerebellar toxicity cerebellar neurological finding exam . Must pregnant breastfeeding . Female patient childbearing potential must agree use dual method contraception negative serum pregnancy test screening , male patient must use effective barrier method contraception sexually active female childbearing potential . Acceptable method contraception condom contraceptive foam , oral , implantable injectable contraceptive , contraceptive patch , intrauterine device , diaphragm spermicidal gel , sexual partner surgically sterilize postmenopausal . For male female patient , effective method contraception must use throughout study three month follow last dose . Patients Down syndrome , acute promyelocytic leukemia , juvenile myelomonocytic leukemia , Fanconi anemia , Kostmann syndrome , Shwachman syndrome , bone marrow failure syndromes eligible . Use investigational agent , exception gemtuzumab ozogamicin , within 30 day . Any significant concurrent disease , illness , psychiatric disorder would compromise patient safety compliance , study participation , follow , interpretation study research . Unstable cardiovascular function : symptomatic ischemia congestive heart failure NYHA Class &gt; 3 myocardial infarction ( MI ) within 3 month Uncontrolled infection require parenteral antibiotic , antiviral , antifungal within one week prior first dose . Infections control concurrent antimicrobial agent acceptable , antimicrobial prophylaxis per institutional guideline acceptable . Known human immunodeficiency virus ( HIV ) infection ( prestudy testing require ) . Patients malabsorption syndrome , disease significantly affect gastrointestinal function . Prior treatment selinexor .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>24 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>